242 related articles for article (PubMed ID: 37042991)
1. Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial.
Huang Y; Chen J; Ding Z; Chen X; Liang X; Zeng X; Xu F; Han Y; Lu H
J Gastroenterol; 2023 Jul; 58(7):633-641. PubMed ID: 37042991
[TBL] [Abstract][Full Text] [Related]
2. Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Suo B; Tian X; Zhang H; Lu H; Li C; Zhang Y; Ren X; Yao X; Zhou L; Song Z
Chin Med J (Engl); 2023 Apr; 136(8):933-940. PubMed ID: 37010246
[TBL] [Abstract][Full Text] [Related]
3. Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.
Chen Q; Zhang W; Fu Q; Liang X; Liu W; Xiao S; Lu H
Am J Gastroenterol; 2016 Dec; 111(12):1736-1742. PubMed ID: 27670603
[TBL] [Abstract][Full Text] [Related]
4. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.
Salmanroghani H; Mirvakili M; Baghbanian M; Salmanroghani R; Sanati G; Yazdian P
PLoS One; 2018; 13(6):e0197096. PubMed ID: 29889843
[TBL] [Abstract][Full Text] [Related]
6. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
7. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.
Hsu PI; Tsai FW; Kao SS; Hsu WH; Cheng JS; Peng NJ; Tsai KW; Hu HM; Wang YK; Chuah SK; Chen A; Wu DC
Am J Gastroenterol; 2017 Sep; 112(9):1374-1381. PubMed ID: 28719592
[TBL] [Abstract][Full Text] [Related]
8. Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Tian XL; Suo BJ; Zhang H; Lu HP; Li CL; Zhang YX; Ren XL; Yao XY; Zhou LY; Song ZQ
Helicobacter; 2023 Feb; 28(1):e12935. PubMed ID: 36374159
[TBL] [Abstract][Full Text] [Related]
9. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
[TBL] [Abstract][Full Text] [Related]
10. Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole.
Gisbert JP; Gisbert JL; Marcos S; Grávalos RG; Carpio D; Pajares JM
Aliment Pharmacol Ther; 1999 Oct; 13(10):1311-6. PubMed ID: 10540045
[TBL] [Abstract][Full Text] [Related]
11. New regimens as first-line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: A randomized controlled trial.
Zhang Y; Suo B; Tian X; Zhang H; Lu H; Yao X; Li C; Ren X; Zhou L; Song Z
Helicobacter; 2023 Apr; 28(2):e12956. PubMed ID: 36752304
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
Uygun A; Kadayifci A; Safali M; Ilgan S; Bagci S
J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.
Bi H; Chen X; Chen Y; Zhao X; Wang S; Wang J; Lyu T; Han S; Lin T; Li M; Yuan D; Liu J; Shi Y
Chin Med J (Engl); 2022 Jul; 135(14):1707-1715. PubMed ID: 36193978
[TBL] [Abstract][Full Text] [Related]
15. Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies.
Wu DC; Hsu PI; Tseng HH; Tsay FW; Lai KH; Kuo CH; Wang SW; Chen A
Medicine (Baltimore); 2011 May; 90(3):180-185. PubMed ID: 21512411
[TBL] [Abstract][Full Text] [Related]
16. New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.
Tursi A; Di Mario F; Franceschi M; De Bastiani R; Elisei W; Baldassarre G; Ferronato A; Grillo S; Landi S; Zamparella M; De Polo M; Boscariolo L; Picchio M
Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28125857
[TBL] [Abstract][Full Text] [Related]
17. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy.
Hsu PI; Chen WC; Tsay FW; Shih CA; Kao SS; Wang HM; Yu HC; Lai KH; Tseng HH; Peng NJ; Chen A; Kuo CH; Wu DC;
Helicobacter; 2014 Feb; 19(1):74-9. PubMed ID: 24033865
[TBL] [Abstract][Full Text] [Related]
18. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
[TBL] [Abstract][Full Text] [Related]
19. Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication.
Song Z; Suo B; Zhang L; Zhou L
Helicobacter; 2016 Dec; 21(6):462-470. PubMed ID: 27060292
[TBL] [Abstract][Full Text] [Related]
20. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Malfertheiner P; Bazzoli F; Delchier JC; Celiñski K; Giguère M; Rivière M; Mégraud F;
Lancet; 2011 Mar; 377(9769):905-13. PubMed ID: 21345487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
